NYSE:ANVS Annovis Bio Q1 2026 Earnings Report $1.88 -0.11 (-5.28%) Closing price 06/5/2026 03:59 PM EasternExtended Trading$1.88 0.00 (0.00%) As of 06/5/2026 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Annovis Bio EPS ResultsActual EPS-$0.63Consensus EPS -$0.40Beat/MissMissed by -$0.24One Year Ago EPSN/AAnnovis Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAnnovis Bio Announcement DetailsQuarterQ1 2026Date5/15/2026TimeBefore Market OpensConference Call DateFriday, May 15, 2026Conference Call Time7:00AM ETUpcoming EarningsAnnovis Bio's Q2 2026 earnings is estimated for Tuesday, August 18, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 14, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Annovis Bio Earnings HeadlinesCritical Survey: Annovis Bio (NYSE:ANVS) and X4 Pharmaceuticals (NASDAQ:XFOR)June 1, 2026 | americanbankingnews.comAnnovis Bio Regains NYSE Listing ComplianceMay 26, 2026 | globenewswire.comTrump’s New Dollar revealedThe last time something like this happened was 1974 - a secret deal that quietly determined the financial fate of an entire generation. According to Porter Stansberry, founder of one of the largest independent financial research firms in the world, it is happening again. Fortune calls it 'the biggest change to the world's relationship with the dollar' in a generation. Stansberry says Trump's money reset - enacted through executive orders and a treaty signed by 13 nations in December 2025 called Pax Silica - could determine whether you are enriched or quietly impoverished by the shift already underway.June 6 at 1:00 AM | Porter & Company (Ad)Annovis Bio slips after pricing $15M equity offeringMay 20, 2026 | seekingalpha.comAnnovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying WarrantsMay 20, 2026 | globenewswire.comAnnovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying WarrantsMay 19, 2026 | globenewswire.comSee More Annovis Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Annovis Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Annovis Bio and other key companies, straight to your email. Email Address About Annovis BioAnnovis Bio (NYSE:ANVS) (NYSE: ANVS) is a clinical-stage biotechnology company headquartered in Tampa, Florida, focused on the discovery and development of small molecule therapeutics for neurodegenerative and neuroinflammatory disorders. Leveraging a proprietary platform that targets protein trafficking and translational dysregulation, Annovis aims to restore cellular homeostasis by modulating the production and clearance of disease-related proteins. The company’s pipeline is designed to address critical pathways implicated in Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and other central nervous system conditions. The company’s lead asset, ANVS401 (Posiphen®), is an oral small molecule that has been evaluated in Phase 1 and Phase 2 clinical trials to reduce levels of amyloid precursor protein and its toxic fragments in Alzheimer’s patients. Preclinical studies suggest that this mechanism may also have applications in mitigating neuroinflammation. In addition to ANVS401, Annovis is advancing a second-generation program, ANVS520, which is aimed at lowering pathological tau and alpha-synuclein aggregates, key drivers of neurodegeneration in Alzheimer’s and Parkinson’s diseases. Both candidates reflect the company’s strategy of targeting multiple disease pathways with a single therapeutic approach. Annovis Bio conducts its clinical trials in North America and Europe, collaborating with academic research centers and contract research organizations to explore safety, pharmacodynamics and biomarker endpoints. The company’s leadership team brings together expertise in neurology, medicinal chemistry and drug development, with a commitment to translating early-stage research into viable treatments. As a publicly traded entity, Annovis continues to engage with scientific and investor communities to advance its programs toward potential regulatory approval.View Annovis Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?A Lulu of a Miss Sends Lululemon to New Lows—Look Out BelowFive Below Down 12% Post Earnings—Is the Selloff Overdone?IREN's 800MW Bet Flips the AI Power SwitchBuy the Dip? Broadcom's AI Moat Is Wider Than EverCrowdStrike Earnings Beat Sparks Selloff—Buy the Dip?The Market Has Ollie’s Bargain Outlet Completely Wrong Upcoming Earnings Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
